News
Stay up-to-date on our latest news.
Stay up-to-date on our latest news.
Feb 20, 2023
Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland ChinaFeb 14, 2023
Clover Launches COVID-19 Booster Vaccine in the People's Republic of ChinaJan 16, 2023
Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023Nov 30, 2022
Clover's Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious DiseasesOct 09, 2022
Clover Provides Update on 2022 Corporate MilestonesSep 20, 2022
Clover's COVID-19 Vaccine Candidate Receives European Union GMP CertificateSep 20, 2022
Clover's Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior Neutralization of Omicron BA.5 Compared to Inactivated VaccineSep 06, 2022
Clover's COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated VaccineAug 30, 2022
Clover's COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5Aug 25, 2022
Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine
